Weiss Multi-Strategy Advisers’s Madrigal Pharmaceuticals MDGL Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-18,060	Closed	-$4.18M	–	285
2023 Q4	$4.18M	Buy	18,060 +625	+4%	+$109K	0.1%	263
2023 Q3	$2.55M	Buy	17,435 +5,435	+45%	+$1.02M	0.06%	344
2023 Q2	$2.77M	Buy	12,000 +3,155	+36%	+$855K	0.06%	412
2023 Q1	$2.14M	Buy	8,845 +7,106	+409%	+$1.94M	0.05%	413
2022 Q4	$505K	Buy	+1,739	New	+$170K	0.01%	513
2020 Q1	–	Sell	-4,200	Closed	-$383K	–	549
2019 Q4	$383K	Buy	+4,200	New	+$407K	0.01%	548
2018 Q3	–	Sell	-3,800	Closed	-$1.06M	–	598
2018 Q2	$1.06M	Buy	+3,800	New	+$667K	0.03%	433

Other funds holding MDGL

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Weiss Multi-Strategy Advisers's MDGL Position: Q1 2024 in Review

Weiss Multi-Strategy Advisers sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2024, closing a stake of 18,060 shares — an estimated $4.18M sold.

Weiss Multi-Strategy Advisers first reported a position in MDGL in Q2 2018 and held it in 7 quarters. The position peaked at $4.18M in Q4 2023. 268 funds tracked by Wall St. Rank hold MDGL as of Q1 2024.

Weiss Multi-Strategy Advisers reported no remaining Madrigal Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 18,060 Madrigal Pharmaceuticals shares in Q1 2024, an estimated $4.18M.
Weiss Multi-Strategy Advisers first reported a position in Madrigal Pharmaceuticals in Q2 2018 and held it in 7 quarters.
Weiss Multi-Strategy Advisers's Madrigal Pharmaceuticals position peaked at $4.18M in Q4 2023.
268 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2024.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q1 2024.